Instil Bio TIL 深 滬
等待開盤 08-22 09:30:00 美东时间
7.58
+0.150
+2.02%
華盛通- 最 高7.88
- 今 開7.40
- 成交量 9204股
- 最 低 7.40
- 昨 收 7.43
- 總市值 5140.74万
- 52周最高 33.833
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 5.67
- 委 比 96.61%
- 總股本 678.20万
- 歷史最高 589.80
- 量 比 1.66
- 振 幅 6.46%
- 歷史最低 0.80
- 每 手 1
- 風險率 5.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 84.37 percent increase over losses of $(2.88) per share from the same period last year.
08-14 05:03
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported its Q2 2026 financial results, highlighting a cash position of $69.9 million as of June 30, 2026, expected to fund operations beyond 2027. The company saw reduced in-process R&D expenses, lower R&D and G&A costs compared to Q2 2025, and a decrease in net loss per share. Instil is evaluating potential acquisitions and in-licensing opportunities to access novel therapeutic candidates.
08-13 21:00
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced that Dr. David Chang will transition from CEO to continue serving on the Board of Directors. Dr. Zachary Roberts, currently EVP, R&D and CMO, will succeed him as President and CEO effective July 1, 2026. Dr. Chang's leadership established Allogene as a leader in allogeneic CAR T therapies, advancing innovative treatments and infrastructure. Dr. Roberts has reshaped the company's clinical strategy, driving advanceme...
05-28 21:02
Instil Bio Non-GAAP EPS of -$0.32
Instil Bio press release (TIL): Q1 Non-GAAP EPS of -$0.32. As of March 31, 2026, Instil had approximately $74.7 million in total cash, cash equivalents, restricted cash and marketable securities, whic...
05-15 19:12
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported its Q1 2026 financial results, highlighting a cash position of $74.7 million, enabling operations beyond 2027. The company is evaluating acquisitions and in-licensing opportunities to expand its pipeline. Q1 expenses included $0.7 million in R&D, $5.3 million in G&A, and $1.0 million in restructuring charges. Net loss per share was $0.62, improving from $4.32 in Q1 2025. CEO Bronson Crouch emphasized strategic progress and fin...
05-15 11:00
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08) per share from the
03-27 19:08
